The data featured in the ESMO poster are from retrospective analyses of results from PLATFORM, a randomized Phase 2 trial that evaluated maintenance therapies such as the anti-PD-1 antibody durvalumab ...
WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (“OncXerna”), a precision medicine company using an innovative RNA expression-based biomarker platform to predict patient ...
BOSTON--(BUSINESS WIRE)--Genialis, a leader in applied data science for the development of precision medicines, today announced it will leverage its proprietary ResponderID AI platform technology to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback